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Abstract 
We estimate willingness to pay for small reductions in the risk of suffering a 
range of morbid health conditions using a stated-preference survey fielded to an 
internet panel that is representative of the US population. The adverse health 
conditions are described using a generic health utility system (EQ-5D). Estimated 
WTP is significantly associated with the reduction in probability of illness and with 
the severity and duration of the health condition. The variation of WTP with severity 
and duration is much smaller than proportionate, which implies that WTP to reduce 
risk is not equal to the expected loss in quality adjusted life years (QALYs) multiplied 
by a constant monetary value per QALY. WTP to reduce risk to another person in the 
household is significantly larger than to oneself, approximately 70 percent larger for 
an adult and 190 percent larger for a child. 
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1. Introduction 
Humans face risks of a wide range of adverse health effects induced by 
environmental and other factors. Although there is a large literature that addresses the 
monetary value of mortality risks (e.g., Viscusi and Aldy 2003, Kochi et al. 2006), 
there are few estimates of the value of reducing risks of nonfatal illness. Policymakers 
need a widely applicable method for estimating the value of morbidity risk in order to 
quantify the health benefits of improvements in environmental quality. 
One approach is to combine preference-based measures of the severity and 
duration of illness, such as the quality-adjusted life year (QALY), with monetary 
estimates of the value of reduced morbidity and mortality. For example, the US Food 
and Drug Administration (FDA) estimates the benefits of averted morbidity by 
multiplying the expected QALY gain by a constant monetary value and adding 
expected medical costs (Robinson, 2007). Johnson et al. (1997), Van Houtven et al. 
(2006), and others have proposed developing a non-linear transfer function to estimate 
monetary values from QALYs. An advantage of this approach is its ability to draw on 
the wealth of existing information about preferences for health conditions in the cost-
utility literature. A review of the literature published through 2001 found 533 original 
studies that used cost per QALY to evaluate health and medical interventions (Bell et 
al. 2001, Neumann et al. 2005). The review has been extended through July 2010, 
yielding more than 2,500 original studies including more than 9,000 health-state 
values (Neumann, personal communication). 
To help assess the prospect of using existing QALY estimates to value 
morbidity risk, we conducted a stated-preference survey to examine the following 
questions: 
• Can changes in health-related quality of life (HRQL) measured by a 
generic index of health status be used to estimate WTP to reduce 
specific morbidity risks? 
• What is the relationship between WTP and QALY values for health 
risks that vary in duration, severity of symptoms, and the attributes of 
health that are impaired? 
• Does WTP depend on characteristics of the health condition in addition 
to those captured by QALYs, such as information conveyed by the 
name of the condition?  
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• How does the value of reducing morbidity risks to children compare 
with the value of reducing similar risks to adults? 
• Does WTP depend on current health or other characteristics of the 
individual at risk? 
• How does the value of reducing morbidity risk depend on respondent 
characteristics such as age, education, and income?  
In the remainder of this section, we describe the theoretical and empirical 
background for the study. First, we briefly review the literature on WTP to reduce 
morbidity risk, focusing on studies that are relevant to QALY measures of health. 
Second, we characterize the specifications of the lifetime utility function for health, 
longevity, and wealth that are consistent with the assumption that preferences over 
health and longevity can be represented by QALYs and examine the implications for 
WTP to increase health and longevity. This theoretical model serves as a baseline for 
developing empirical models that describe how WTP to reduce risk depends on the 
severity and duration of the health effect. Third, we justify the use of household WTP 
for valuing health. We describe the research design and methods in Section 2, present 
empirical results in Section 3, and draw conclusions in Section 4. 
Prior Work on Valuing Morbidity  
There are several approaches to valuing morbidity risk. Cost-of-illness 
methods (COI, Rice 1966) measure direct and indirect costs of morbidity, such as 
medical expenditures and lost productivity, but do not capture the non-monetary costs 
of illness, such as pain and suffering. As a result, COI estimates are generally 
considered to be inferior to estimates derived from theoretically correct measures of 
economic benefit, such as WTP. COI information concerning the external costs of 
impaired health (e.g., insured medical expenses, sick pay) may provide a useful 
supplement to WTP information that captures only the private benefits of better 
health. 
Preliminary efforts to explore the relationship between WTP and QALYs 
include work by O’Brien and Viramontes (1994), Cutler and Richardson (1997), 
Krabbe et al. (1997), and Bala et al. (1998). Similar to current FDA practice, Tolley et 
al. (1994) place monetary values on alleviation of a wide range of health conditions 
by assuming that WTP is proportional to QALYs gained. In direct elicitations, they 
observe that WTP is less than proportional to duration of improved health.  
3  
Jones-Lee et al. (1995) elicit WTP to reduce the probabilities of fatality and of 
six injuries of varying severity from motor-vehicle crashes and elicit probabilities of 
fatality for a standard gamble between fatality and complete recovery that respondents 
view as indifferent to the specified injury. They find that the ratio of WTP to prevent 
injury to WTP to prevent fatality is much larger than the complement of the standard 
gamble probability for the corresponding injury, which implies WTP is less than 
proportional to severity as measured by standard gamble. 
In a meta-analysis of studies that estimate WTP to alleviate a total of 53 short-
term health conditions described by duration and HRQL (measured by the Quality of 
Well-Being Scale or QWB, Kaplan et al. 1993), Johnson et al. (1997) find a nonlinear 
relationship between WTP and QALYs. Estimated WTP increases at a decreasing rate 
with duration and severity. Van Houtven et al. (2006) expand on this work by 
including 236 estimates of WTP to prevent acute health impairments. They find that 
WTP increases less than proportionately with duration and more than proportionately 
with the severity of illness. They also find that WTP and the QWB respond differently 
to health attributes: WTP is significantly associated with QWB scores for mobility 
and physical activity but not for symptoms and social activity.  
Johnson et al. (2000) and Gyrd-Hansen (2003) apply discrete-choice modeling 
to value changes in hypothetical acute respiratory and cardiovascular illness and 
chronic health states, respectively. Both studies find evidence of a nonlinear 
relationship between WTP and QALYs as well as variation in WTP for different 
attributes of health. 
Byrne et al. (2005) and King et al. (2005) assess current health and elicit WTP 
for hypothetical treatments that would yield perfect health in various populations 
suffering chronic health conditions (Byrne et al. also assessed health and WTP for two 
hypothetical health states). Mean WTP was on the order of $10,000 (Byrne et al., 
2005) and $100,000 (King et al., 2005), much larger than conventionally assessed in 
stated-preference studies and implying non-marginal changes in disposable income. 
Hammitt and Haninger (2007) elicited WTP to reduce the risk of acute illness 
(1, 3, or 7 days) from foodborne pathogens. They found that WTP varied significantly 
with the reduction in probability of harm, severity, and duration of illness. Using the 
same data, Haninger and Hammitt (2011) estimated the elasticities of WTP with 
respect to duration and severity as about 0.1 and 0.2, respectively, much smaller than 
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the elasticity with respect to risk reduction (0.5) and the value of one required if WTP 
is proportional to expected gain in QALYs. 
Pinto-Prades et al. (2009) elicited WTP per month for improved treatment of a 
temporary health impairment (that would shorten its duration or reduce its severity) 
and to halve or eliminate a 1 percent risk of developing a chronic (lifetime) 
impairment. The impairment was characterized solely by EQ-5D profile. They found 
that WTP increased with duration and severity of the impairment but much less than 
proportionately. A factor causing concern about their results is that monthly WTP, 
which averaged 50-100€, was insensitive to whether the respondent would be required 
to pay for 12 or 24 months.  
Theoretical Background 
WTP and QALYs represent alternative methods of assigning values to health 
risks. WTP is the amount of money available for consumption that an individual 
views as providing the same utility as the specified change in health risk. WTP is 
defined as the compensating variation, i.e., the maximum amount of money an 
individual would exchange for the reduction in health risk. A closely related measure, 
WTA (willingness to accept compensation) is defined as the equivalent variation, i.e., 
the minimum amount of money an individual would accept to forego the reduction in 
health risk. For small changes in risk, WTP and WTA should be nearly equal, 
although differences can arise for large changes in risk or when the risk change has no 
close substitutes (Hanemann 1991). Standard economic theory places little constraint 
on how WTP varies with health risk, except that WTP should increase with the 
severity of the harm avoided and, for small reductions in the probability of harm, 
WTP should be nearly proportional to the change in probability (Hammitt 2000, 
Corso et al. 2001). 
QALYs are an alternative measure of individual utility for health that impose 
more structure on preferences. If an individual’s preferences for health are consistent 
with QALYs, they must satisfy several conditions including mutual utility 
independence between health and longevity and constant proportional tradeoff of 
longevity for health (Pliskin et al. 1980), or risk neutrality over longevity for any 
health state and indifference to health quality for periods of zero duration (Bleichrodt 
et al. 1997). In addition, preferences for health and longevity are assumed to be 
independent of income (Hammitt 2002a). 
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If an individual’s preferences for future health and longevity can be 
represented by QALYs, then his utility function for his remaining lifetime with health 
h, longevity T, and wealth w must be a positive linear function of future QALYs and 
can be represented as 
  ܷሺ݄, ܶ, ݓሻ ൌ ܳܽሺݓሻ ൅ ܾሺݓሻ     (1) 
where Q is future QALYs and a(w) and b(w) are functions of wealth.1 Since utility is 
increasing in QALYs, a(w) > 0. Under the standard assumption that the individual 
never prefers to die with less wealth, b′(w) ≥ 0. If the marginal utility of wealth is 
non-decreasing in health and longevity, then a′(w) ≥ 0. Assuming the marginal utility 
of wealth while living is positive requires a′(w) > 0 or b′(w) > 0 (Hammitt 2002b). 
Individual WTP per QALY can be characterized by differentiating equation 
(1) to obtain the margi  substitu n bet e  wealth and future QALYs, nal rate of tio w en
  ܸ ൌ െௗ௪
ௗொ
ൌ ௔
ሺ௪ሻ
ொ௔ᇲሺ௪ሻା௕ᇲሺ௪ሻ
൅ డ௪
డொ
.    (2) 
The marginal rate of substitution V depends on two terms. The second term is the 
“indirect” effect of health and longevity on wealth, which includes any changes in 
income and private medical expenditures that result from better health and longevity. 
The first term represents the “direct” effect of health and longevity on utility and 
depends on wealth. For simplicity, assume the effect on wealth is negligible in 
comparison with the direct effect. The direct effect is bounded by two cases. If the 
marginal utility of wealth is independent of health and longevity, a′(w) = 0 and V is 
independent of future QALYs. If the individual is indifferent to the level of his 
bequest, b′(w) = 0 and V is inversely proportional to future QALYs. Otherwise, V 
declines with future QALYs but less than proportionately.  
Household WTP as a Measure of the Value of Health 
There are a variety of reasons why children’s own WTP for health and safety 
initiatives are not appropriate measures of the value of these goods to children. 
Children differ from adults in ways that present problems for the standard economic 
assumptions of informed and rational behavior (Harbaugh 1999). For example, 
                                                 
1 This follows because the utility function for health and longevity conditional on any 
level of wealth must be strategically equivalent (i.e., imply the same preferences over 
lotteries on health and longevity). See Keeney and Raiffa (1976). 
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children have incompletely developed reasoning abilities and typically do not have 
income or authority over spending.  
While children’s own WTP may be an inappropriate measure of value, 
household WTP is an appropriate starting point. Understandably, parents know and 
care about their children’s health and are accustomed to making economic decisions 
that will affect their children. To some extent, economists may view parental choices 
as altruistic behavior, but they may also regard households as unitary economic agents 
with preferences and behaviors that are the result of some intra-household decision-
making process.  
Although much of the literature on the value of health risk treats the concept 
as measuring an individual’s rate of substitution between income and risk, in both 
theory and practice it seems more tenable to interpret this literature as measuring 
household WTP for changes in risk. In some cases, the change in risk is to a defined 
individual (e.g., the worker in studies of compensating wage differentials). In other 
cases, the risk change may benefit the entire household (e.g., studies valuing the risk 
of residential proximity to hazardous-waste sites; Smith and Desvousges 1987, Gayer 
et al. 2000, Davis 2004). In all cases, the opportunity cost of a risk reduction is less 
income available to the household for spending on other goods. Depending on how 
households allocate consumption among their members, some or all of them may 
have lower consumption as a result. 
2. Survey instrument 
We administered a stated-preference survey to a sample from a nationwide 
internet panel hosted by Knowledge Networks. Panel members were recruited through 
random digit dial and closely match the US population on measurable demographic 
and socioeconomic factors. 
Respondents were asked to value reductions in risk of a nonfatal illness that 
might affect a specified “target:” themselves, a child, or another adult living in their 
household. (If the household includes more than one child or other adult, the target 
was randomly selected.) Respondents valued two risk reductions to themselves and 
two each to a child and to another adult if present in the household. By valuing risks 
to another adult in the household, we can distinguish two effects that may contribute 
to any difference between the value of reducing risk to oneself and to one’s child: self 
vs. other and adult vs. child. The order of targets was randomized. 
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The morbid condition was described using the EQ-5D, a generic health-state 
classification and utility system that characterizes health states using five attributes 
(mobility, self-care, usual activities, pain/discomfort, and anxiety/depression; 
EuroQol Group 1990). Each attribute can take one of three levels (1 = no problems, 2 
= moderate problems, 3 = severe problems). The health-related quality of life (HRQL) 
associated with a health state is a measure that is normalized to one for perfect health 
and zero for health states equivalent to dead (negative values are permitted for states 
worse than dead). It can be calculated by applying a scoring rule to the EQ-5D health-
state description. For half the respondents, the name of the disease or health condition 
causing each morbid condition was provided; for the other half, conditions were 
described by the EQ-5D profile alone. The EQ-5D profiles that were presented are 
typical profiles reported by individuals having the named health states as reported in 
the Medical Expenditure Panel Survey (MEPS) conducted by the US Agency for 
Healthcare Research and Quality (some illness names are associated with multiple 
profiles). The duration of the morbidity was varied among three values: a month, a 
year, and remainder of lifetime. Combinations of duration with condition name and 
associated EQ-5D profiles that are unrealistic were excluded.  
The EQ-5D profiles, durations, and condition names included in the survey are 
presented in Table 1. For each profile, we report the corresponding HRQL estimated 
using the scoring rule developed by Shaw et al. (2005) using preferences for health 
states elicited from a large representative sample of the US population. The HRQL for 
these EQ-5D profiles ranges from a maximum of 0.827 to a minimum of 0.086. The 
maximum is obtained for health profile A, for which the pain/discomfort attribute is at 
its second level and all the other attributes are at their first (best) levels (labeled M1 
S1 U1 P2 A1, see Table 1 note). This profile is associated with influenza, respiratory 
infection, and skin cancer. The minimum HRQL is for health profile K, which is 
associated with heart disease. For this profile, the mobility and pain/discomfort 
attributes are at their worst levels and the other three attributes are at their 
intermediate levels (M3 S2 U2 P3 A2). All of the attributes take on each of the three 
possible levels for some health profile with the exception of pain/discomfort, which is 
always at level 2 (moderate pain or discomfort) or level 3 (extreme pain or 
discomfort). Although the health conditions were described as nonfatal, some of the 
diseases are often fatal and respondents presented with these condition names may 
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incorporated this factor in their valuation. In addition, the use of fixed EQ-5D profiles 
oversimplifies the usual deterioration in health as some diseases progress. 
The baseline risk of illness and intervention for reducing it were presented in 
rather abstract terms, as in some previous stated-preference studies (e.g., Krupnick et 
al. 2002 and subsequent studies using their survey instrument, Cameron et al. 2010). 
The risk was described as an annual risk resulting “from exposure to environmental 
contaminants” and could be reduced by participating in a US government 
environmental health protection program that includes an annual screening test and 
preventive medicine. The baseline risk was stated to be either 3 or 4 per 10,000 per 
year, and participation in the program would reduce it by either 1 or 2 per 10,000 per 
year (initial risk and risk reduction were varied randomly). The baseline risk, 
reduction in risk, and final risk were illustrated using grids containing 10,000 squares, 
in which the number of red squares corresponded to the risk after reduction (1, 2, or 
3), the number of white squares to the risk reduction (1 or 2), and the total number of 
the red and white squares to the baseline risk (3 or 4). This approach is adapted from 
the best-performing of the visual aids tested by Corso et al. (2001) to help 
communicate small risk changes to survey respondents. Willingness to pay an annual 
fee for the risk reduction was elicited using double-bounded dichotomous-choice 
questions in which the additional cost to the respondent’s household was varied 
(Hanemann et al. 1991); the follow-up bid was twice the initial bid for respondents 
who indicated they would choose the risk reduction and half the initial bid for other 
respondents. 
To introduce the survey, respondents were asked to indicate their degree of 
concern about several types of health risks (air pollution, water contamination, 
occupational, aircraft and motor-vehicle crashes) on a five point scale. Next, they 
were presented with two practice valuation questions with feedback. These questions 
involved a choice between two types of food at a grocery store, in which the risk of 
illness and price varied between the two types. In the first question, one type of apple 
was both safer and less expensive than the other type of apple. Respondents who 
chose the dominant alternative were told that the type they had selected was both safer 
and less expensive than the other and that this was the logical choice. Respondents 
who chose the dominated alternative were told that the type they had selected was 
both less safe and more expensive than the other and invited to choose again. In the 
second practice question, between two types of grape, neither alternative was 
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dominant. Respondents were told the type they had chosen was safer and more 
expensive, or less safe and less expensive, as appropriate and asked to confirm that 
was the choice they preferred.  
Following the practice questions, the respondent was asked to describe the 
current health of each of the targets in his or her household (i.e., the respondent, a 
child younger than 18 years, and another adult living in the household; in households 
with multiple children or other adults, one was selected at random). For each target, 
the respondent was asked to describe the target’s current health using both EQ-5D 
(described above) and visual-analog scales. The visual-analog scale is a linear scale 
with numbers ranging from 0 to 100 that are associated with health states as bad as 
dead and as good as perfect health, respectively. The respondent was asked to select a 
number on this scale that corresponds to current health. In addition, the respondent 
was asked to estimate each target’s life expectancy and to rate his or her current 
health using a time-tradeoff question that elicits the number of years in perfect health 
that are viewed to be equally desirable as the life expectancy if lived in current health. 
(Respondents who declined to estimate life expectancy were told the life expectancy 
for someone of the target’s age and gender.) 
For each risk to be valued, the respondent was first presented with the 
description (EQ-5D profile, duration, and, for half the respondents, condition name) 
then asked to rate the target’s health conditional on having this condition using a 
visual-analog scale. To ensure that the illness never implied an improvement in 
health, each attribute in the EQ-5D profile presented to the respondent was set equal 
to the maximum (i.e., worst) of the level presented in Table 1 and the level 
corresponding to the target’s current health. In most cases, the target’s current value 
on each attribute was no worse than the level specified in the profile in Table 1 and no 
substitution was required. 
The HRQL for the target’s current health and for each EQ-5D profile was 
calculated using a scoring algorithm estimated for the US population (Shaw et al. 
2005) and the loss in HRQL while ill was calculated as the difference between these 
values. An alternative measure of the loss in HRQL was calculated as the 
corresponding difference in the HRQL estimates obtained from the visual-analog-
scale questions. While the measured based on the EQ-5D assumes the function 
linking impairments on each attribute to HRQL is common across individuals, the 
visual-analog-scale imposes no such restrictions and is respondent-specific. 
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The valuation question for each risk followed. By asking the respondent to 
evaluate health conditional on having the condition immediately prior to the valuation 
question we attempted to focus his or her attention on the characteristics of the disease 
risk to be reduced. 
3. Results 
Sample characteristics 
Variables are identified in Table 2 together with their means and standard 
deviations for the full data set and the subsamples corresponding to questions about 
reducing risk to each target. As intended, randomly assigned design variables such as 
baseline risk and whether the illness is named have mean values of approximately one 
half in all subsamples. Current health-related quality of life is larger for a child than 
an adult, which is expected because the frequency of adverse health conditions 
increases with age. Consequently, the log of the loss in health-related quality of life 
conditional on having a specified morbidity is also larger for a child than for an adult 
target. The log of the duration of illness is substantially larger for a child than an adult 
because the lifetime illness has greater expected duration.  
Of the 2,184 respondents, 727 (33 percent) have one or more children younger 
than 18 years living in the household and 1,668 (76 percent) have at least one other 
adult living in the household. The average respondent having a child in the household 
(38 years) is a decade younger than the average of all respondents (48 years). 
Household income for respondents with a child or other adult in the household 
($68,000) is larger than for the average respondent ($62,000). Respondent’s education 
is similar across subsamples (almost 14 years). Race and ethnicity are also similar, 
except that Hispanic respondents are more frequently included in the subsample 
having a child in the household than in other subsamples (13 percent compared with 9 
percent). 
Estimated WTP to reduce risk 
Regression models describing WTP to reduce risk are estimated using 
maximum-likelihood methods assuming a lognormal error distribution to 
accommodate the interval-censored data that result from using double-bounded 
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dichotomous-choice questions (Alberini 1995). The models can be interpreted as 
describing the natural logarithm of WTP. 
Table 3 reports the results of our basic model that characterizes WTP as a 
function of the initial risk, log risk reduction, log loss in HRQL, log duration of 
illness, the target’s current HRQL, plus indicator variables for whether the illness is 
named and for whether the target individual’s current health is equal to the illness 
presented in the survey. By including an indicator variable for cases in which HRQL 
loss is zero, we avoid the possibility that the estimated coefficient on the log of HRQL 
loss will be influenced by the arbitrary value we assign that variable in these cases. 
Table 3 reports four models, estimated on the full sample of responses to 
valuation questions pooling across targets (Model 1) and separately for the two 
questions valuing risk to the same target (Models 2-4).2 The estimated coefficients are 
reasonably similar across the pooled and subsample models. Only the coefficient on 
the baseline-risk variable (equal to 1 if the baseline risk is 4 in 10,000 per year and 0 
if it is equal to 3 in 10,000 per year) does not significantly differ from zero. The 
insensitivity of estimated WTP to this small difference in baseline risk is consistent 
with economic theory. 
The estimated coefficient on the log of risk reduction (approximately 0.6) is 
significantly different from zero, which implies that respondents are sensitive to the 
magnitude of the risk reduction, despite its small size, and constitutes strong evidence 
that respondents were attentive to the specification of the risk reduction. Economic 
theory implies that WTP should be nearly proportional to the reduction in probability 
of illness for these small reductions (Hammitt 2000, Corso et al. 2001). We can reject 
the hypothesis that WTP is proportional to risk reduction (i.e., that the coefficient on 
log risk reduction equals one) for the pooled model (Model 1; p = 0.003) and for the 
model of WTP to reduce risk to self (Model 2; p = 0.05) but not for the model for risk 
to child (Model 3; p = 0.21) or risk to other adult (Model 4; p = 0.06), perhaps 
because of the smaller sample sizes and larger standard errors for the last two models. 
In models for reducing risk to a target identical to those shown in Table 3 but 
estimated using only data from respondents who answered the valuation question 
about that target first (i.e., before answering questions about other household 
                                                 
2 The numbers of observations for Models 2-4 are slightly less than twice the 
corresponding sample sizes shown in Table 2 because some respondents answered 
only one valuation question for a target. 
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members), the estimated coefficients on log risk reduction are between 0.86 and 1.02 
suggesting that WTP is proportional to risk reduction.3 
Estimated WTP is sensitive to the severity and duration of the potential 
morbidity but varies much less than in proportion to these variables. The estimated 
coefficient on log of the loss in HRQL can be interpreted as the elasticity of WTP 
with respect to an increase in the severity of the condition (measured by the loss of 
HRQL from current health). The estimated values are about 0.4 for risks to self or to 
another adult and 0.2 for risk to a child. These coefficients are significantly different 
from zero (except for the risk to child) and also from one. Measuring HRQL loss 
using visual-analog scores yields similar results, except the estimated elasticity for 
risk to a child increases to about 0.4 and is significantly different from zero.4  
The estimated elasticity of WTP with respect to duration of illness is also 
significantly different from zero and from one and even smaller in magnitude: about 
0.1 for all three targets. We tested whether using the log of duration accurately 
captures the relationship between duration and WTP by supplementing the models 
shown in Table 3 with an indicator variable for one year duration (the alternative 
values are one month and remaining lifetime). The estimated coefficient on this 
variable is small in absolute value (ranging between -0.18 and 0.05) and smaller than 
its standard error in all four models, which suggests that the effect of duration is 
adequately represented using the logarithmic specification.5 Together, the findings 
that estimated WTP varies much less than in proportion to the severity and duration of 
                                                 
3 Estimated coefficients (standard errors) on log risk reduction are 0.969 (0.188) for 
the pooled model, 1.017 (0.243) for the model of WTP to reduce risk to self, 0.864 
(0.637) for the model for risk to child, and 0.902 (0.332) for the model for risk to 
another adult. 
4 Estimated coefficients (standard errors) on log loss in HRQL based on the visual-
analog scores assigned by respondents are 0.412 (0.065) for the pooled model, 0.433 
(0.095) for the model of WTP to reduce risk to self, 0.421 (0.165) for the model for 
risk to child, and 0.319 (0.109) for the model for risk to another adult. 
5 Because the diseases with high mortality risk (e.g., lung cancer, liver cancer, 
Parkinson’s disease) are always characterized as lifetime, one might expect that the 
estimated coefficient on duration is biased upward. Indeed, when the models in Table 
3 are estimated using only the subsample that was not presented with disease names, 
the estimated coefficients on log duration are somewhat smaller than reported in 
Table 3. The estimated coefficients (standard errors) for Models 1 – 4 estimated on 
the subsample without disease names are 0.072 (0.024), 0.080 (0.036), 0.101 (0.056), 
and 0.052(0.040), respectively. These coefficients are similar to the coefficients 
estimated for models that include disease names, reported in Table 5 below. 
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the illness imply that WTP is much less than proportional to the loss in QALYs 
associated with an illness, and so WTP to avoid a loss of QALYs is a sharply 
decreasing function of the quantity of QALYs at stake. 
The estimated coefficient on the variable indicating that the name of the illness 
was specified is highly significant and less than zero. This implies that WTP to reduce 
risk is substantially smaller when the illness is described by name and EQ-5D profile 
rather than by EQ-5D profile alone. The estimated magnitude of the effect ranges 
between a 30 percent reduction when the target is another adult and a 60 percent 
reduction when the target is a child.6 Although one might have anticipated that 
naming the health condition would make it more realistic and salient, and perhaps 
increase WTP, we find the opposite result. One possible explanation is that many of 
the illnesses may be perceived as relatively mild (e.g., influenza, respiratory infection) 
and so supplementing the EQ-5D profile with the name may have caused respondents 
to believe the illness was less serious. Alternatively, naming the conditions may have 
made them more familiar and less dreaded than when they are described only by the 
EQ-5D profile (e.g., Slovic 1987). 
In the pooled model (Model 1), the coefficients of the indicator variables for 
target are large and highly significant. These imply the respondent will pay about 70 
percent more to reduce risk to another adult and 190 percent more for a child in his or 
her household. Comparing these values suggests that the larger WTP to reduce risk to 
a child than to the respondent him or herself is composed of two effects: larger WTP 
to reduce risk to someone else in one’s household rather than to oneself (a premium of 
70 percent) and larger WTP to reduce risk to a child than to another adult (also a 
premium of 70 percent). 
Effects of respondent characteristics 
Table 4 reports estimates of models similar to those in Table 3 with the 
addition of demographic and economic characteristics of the respondent and target. 
Estimated coefficients of the variables included in the basic model are virtually 
identical to those in Table 3. 
Estimated WTP to reduce risk to one’s child or to another adult in the 
household varies with the sex of the child and with the age and sex of the other adult. 
                                                 
6 Note: 30 percent ≈ 1 – exp(-0.396), 60 percent ≈ 1 – exp(-0.921). 
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The estimated coefficients imply that the respondent will pay about 4 percent more to 
reduce risk to a male child and 33 percent more to reduce risk to a male adult. WTP 
increases with the age of the other adult in the household, at a rate of approximately 1 
percent for every decade of age.  Estimated WTP also varies significantly with several 
respondent characteristics. WTP increases with respondent age, at a rate of 
approximately 16 percent for every decade of age in the pooled model and similar 
rates in the other models. Married respondents have significantly smaller WTP for all 
targets and male respondents are estimated to have smaller WTP for themselves, 
though not for others in the household, suggesting that men are stoic but no less 
altruistic than women. WTP is estimated to increase with respondents’ education, 
though the effect is statistically significant only for risk to another adult and in the 
pooled model. The coefficient in the pooled model suggests that WTP increases about 
4 percent with each year of education. The effect of household income is significantly 
positive for WTP to reduce risk to oneself or one’s child, though not to reduce risk to 
another adult. The estimated income elasticity is about 0.3 for reducing risk to oneself 
and one’s child, toward the lower end of previous estimates (Hammitt and Robinson 
2011). 
Effect of condition name 
To examine how WTP varies with the illness named, we report in Table 5 a set 
of models that are identical to the basic models in Table 3 supplemented with 
variables indicating the specific illness named (recall that the illness is not named for 
half the respondents). Adding these indicator variables has no significant effect on the 
estimated coefficients for the log of risk reduction but the estimated coefficients on 
the log of HRQL loss and log duration of illness are somewhat smaller than in the 
corresponding models in Table 3. In the pooled model, for example, the coefficient on 
log HRQL loss decreases from 0.37 in Table 3 to 0.30 in Table 5 and the coefficient 
on log duration decreases from 0.13 to 0.07. 
Of the 11 named conditions, the estimated coefficients of six are significantly 
different from zero in the pooled model (Model 1, Table 5). All are less than zero, 
implying that WTP to reduce the risk of these named diseases is smaller than WTP to 
reduce the risk of an unnamed disease having the same EQ-5D profile. Ranking these 
diseases in decreasing order of the absolute value of the estimated coefficient yields 
skin cancer, influenza, migraine headache, hepatitis, bronchitis, and respiratory 
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infection. Evidently, respondents view these diseases as mild compared with the 
associated EQ-5D profiles. In contrast, the estimated coefficients on the other five 
diseases (Parkinson’s disease, heart disease, liver disease, liver cancer, and lung 
cancer) are not significantly different from zero, implying that WTP to reduce risk of 
these diseases is no smaller than to reduce the risk of an unnamed disease having the 
same EQ-5D profile. The larger WTP to reduce risks of these diseases (controlling for 
HRQL) may also reflect respondents’ recognition that these diseases are often fatal. 
Estimates of the models for each target reveal similar patterns of point 
estimates, though fewer estimates are significantly different from zero. One exception 
is that the estimated coefficient for lung cancer when the risk is to another adult 
(Model 4) is significantly different from zero. The estimated coefficient implies that 
WTP to reduce this risk is almost 140 percent larger than for an unnamed disease with 
the same EQ-5D profile.  
WTP by EQ-5D attribute 
In the models reported in Tables 3, 4, and 5, severity of illness is measured as 
the log of the loss in HRQL between a target’s current health and health if he or she 
develops the stated illness. We examine the relationship between WTP and potential 
health loss using two approaches: estimate WTP using a model including information 
on each attribute at baseline and if ill, and estimate WTP as a function of losses on 
each attribute using a model that is based on the Shaw et al. (2005) scoring function. 
The models reported in Table 6 supplement the basic model (Table 3) with 
variables characterizing the levels of each of the EQ-5D attributes for the target’s 
current health and health if he or she suffers the specified illness (log HRQL loss is 
omitted).7 The results suggest that WTP to reduce risk of illness varies with baseline 
levels and potential losses on the different attributes. When the target is an adult (the 
respondent or another adult), estimated WTP to reduce risk is larger when current 
health includes pain/discomfort and impairments in carrying out usual activities, and 
smaller for targets whose current health includes impairments in self-care. Estimated 
                                                 
7 The variables for baseline impairment of each attribute are defined as the 
corresponding level of the EQ-5D attribute for current health minus one; i.e., 0 if the 
target’s current health includes no impairment on that attribute, 1 for moderate 
impairment, and 2 for severe impairment. The variables for loss on each attribute are 
defined as the difference between the level of the attribute if ill and the level at current 
health and can take the values 0, 1, and 2. 
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WTP is larger when the illness produces a loss in mobility and (for another adult) a 
loss in usual activities or pain/discomfort. When the target is a child, WTP to reduce 
risk is smaller if the child has impaired mobility at baseline. Estimated WTP is more 
sensitive to baseline health than to the incremental impairment if ill: the absolute 
value of the coefficient on baseline impairment is larger than that on impairment for 
three or four of the five attributes in all four models. 
Estimated coefficients of the other variables are similar to their values in the 
corresponding basic model (Table 3). The elasticity of WTP with magnitude of risk 
reduction is about 0.6 and that with duration is about 0.1. On average, WTP to reduce 
risk of a named illness is much smaller than for a corresponding unnamed illness, and 
WTP is larger when the target is a child or other adult. 
Table 7 reports estimates of a model that is based on the model developed by 
Shaw et al. (2005) to calculate HRQL for each EQ-5D profile. This model can be 
used to examine whether WTP and HRQL bear similar functional relationships to EQ-
5D profile. In addition to variables from the basic model, the independent variables 
include indicator variables for the loss (from current health) to level 2 or level 3 on 
each attribute, plus variables for the change in the number of attributes at level 2 or 3 
and their squares. 
The first column reports the coefficients of the Shaw et al. (2005) model. 
These coefficients estimate the decrement in HRQL associated with a loss from level 
1 to the indicated level on each attribute. Note that the effect of loss to level 3 exceeds 
that of loss to level 2 for each attribute, as one would anticipate. In the pooled WTP 
model (Model 1), it is also true that the increase in WTP is larger when the illness 
would produce a loss to level 3 than a loss to level 2 on each attribute.  
In contrast, the relative effect of losses on different attributes differs between 
the HRQL value function and the WTP models. For both the HRQL value function 
and the pooled WTP model, the attribute for which a loss to level 3 has the largest 
effect is mobility. In contrast, the attribute with the second largest effect in the HRQL 
value model is pain/discomfort, though this attribute has the least effect in the WTP 
model. The attribute with the second largest effect in the WTP model is 
anxiety/depression, though this attribute has only the fourth largest effect in the 
HRQL value function. 
Overall, the results of Tables 6 and 7 suggest that WTP to reduce risk of a 
health loss described by the change in EQ-5D profile is not adequately captured by 
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the loss in the summary measure of HRQL calculated using the Shaw et al. (2005) 
scoring function. Adding a variable for log of HRQL loss to the models reported in 
Table 7 confirms this result, as doing so has little effect on the estimated coefficients 
reported in Table 7. WTP depends on the baseline levels and losses on each attribute 
in a pattern that differs from the difference in calculated HRQL.  
4. Conclusions 
We have examined the relationship between two alternative metrics for 
valuing health risk, WTP and QALYs, in the context of acute and chronic morbidity. 
A practical motivation is to determine whether it is possible to estimate WTP to 
reduce risk of a morbid health condition by transferring from an estimate of the 
expected QALY loss. Such an approach would be valuable because there are few 
direct estimates of WTP to reduce morbidity risk and many estimates of the QALY 
loss associated with adverse health conditions. Moreover, it is comparatively easy to 
estimate the QALY loss associated with an adverse health condition because the 
HRQL can be estimated using generic health-state classification and utility systems 
(such as the EQ-5D) and combined with an estimate of the duration of the health state. 
For example, Lawrence et al. (2006) estimated the QALY loss associated with several 
conditions by asking a small sample of physicians and others familiar with these 
conditions to classify them using the EQ-5D and analogous systems, from which the 
HRQL could be calculated.  
In a large stated-preference survey, we presented respondents with risks of 
nonfatal health conditions described by EQ-5D profile and duration. For half the 
respondents, the disease or illness was also named. We elicited WTP to reduce risk to 
the respondent him or herself and to a child and other adult living in the respondent’s 
household. The risk was presented as resulting from exposure to environmental 
contaminants and to be reducible by participating in a government environmental 
health protection program that includes an annual screening test and preventive 
medicine. WTP was elicited using standard double-bounded dichotomous-choice 
questions. 
As a test of respondent comprehension and quality of response, we randomly 
varied the reduction in probability of illness between 1/10,000 and 2/10,000 per year. 
In all of our regression models, WTP varies with the magnitude of risk reduction. The 
estimated elasticity of WTP with respect to risk reduction is about 0.6 and is 
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statistically significantly different from zero. Although (for some models) it is 
significantly smaller than the value of one implied by economic theory, this value is 
larger than obtained in many stated-preference surveys and indicates that the 
respondents were attentive to differences in risk reduction across valuation questions.8 
We find that WTP to reduce risk is significantly related to the QALY loss 
from illness but the variation is less than proportionate. The elasticity of WTP with 
respect to the loss in HRQL (the difference between the individual’s current HRQL 
and its value if ill) is about 0.3 and the elasticity of WTP with respect to duration of 
illness is about 0.1. These results imply that WTP to reduce risk is not proportional to 
the expected reduction in QALYs lost, and so WTP to reduce morbidity risk cannot 
be accurately estimated by multiplying the reduction in expected QALYs lost by a 
constant WTP per QALY value. One might be concerned that the elasticities of WTP 
with respect to severity and duration are underestimated because of some form of 
scope insensitivity in our survey instrument. However, it seems implausible that scope 
insensitivity would have a larger effect on attributes such as severity and duration that 
are likely to be well understood by respondents than on attributes such as the small 
reduction in probability of illness for which respondents may have little appreciation, 
and for which the estimated elasticity (0.6) is much larger. 
Describing the illness by name as well as EQ-5D profile reduces the estimated 
WTP on average. This reduction obtains only for the milder diseases considered 
(influenza, respiratory infection, skin cancer), not the more severe (e.g., lung cancer, 
liver cancer, liver disease, heart disease). The statistically significant effect of disease 
name (at least for some conditions) implies that the information about health state 
provided by an EQ-5D profile is not sufficient; i.e., respondents are not indifferent to 
reducing risk of different illnesses having the same EQ-5D profile. For some diseases, 
this additional information may include recognition of significant mortality risk. 
We find that WTP to reduce risk to another person exceeds WTP to reduce 
risk to oneself. WTP to reduce risk to another adult in the household is estimated to be 
70 percent larger than WTP to reduce risk to oneself and WTP to reduce risk to a 
child living in the household is an additional 70 percent larger, yielding a combined 
premium relative to WTP to reduce risk to self of 190 percent. 
                                                 
8 As noted above, in models estimated using only information about the first target 
valued, the estimated coefficient is very nearly one. 
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We also evaluate WTP to reduce morbidity risk as a function of pre-existing 
health and the decrements associated with the stated illness on each of the five EQ-5D 
attributes. The results suggest that WTP to reduce risk to an adult (the respondent or 
other adult) is larger when current health includes pain/discomfort and impairments in 
carrying out usual activities and smaller for targets whose current health includes 
impairments in self-care. Estimated WTP is larger when the illness produces a loss in 
mobility and (for another adult) a loss in usual activities or pain/discomfort. When the 
target is a child, WTP to reduce risk is smaller if the child has impaired mobility at 
baseline. Comparing the effect of losses on each EQ-5D attribute on WTP and on the 
HRQL as calculated using a scoring function developed for the US population (Shaw 
et al. 2005) suggests that the functional relationships between these measures and EQ-
5D profile differ: although loss of mobility is the most influential attribute for both, 
the relative importance of other attributes differs between the measures.  
The estimated value per statistical case depends on the severity and duration of 
morbidity as well as the individual at risk. For illustration, consider an unnamed 
illness of one year duration that reduces HRQL by 0.1. Using the target-specific 
models reported in Table 3 (Models 2 – 4), assuming perfect current health, and 
averaging over the two values of risk reduction, the predicted median values per 
statistical case are $650,000, $2.9 million, and $780,000 for the respondent, a child, 
and another adult living in the household, respectively. For a very severe case of 40 
year duration that reduces HRQL by 1.0 (i.e., from perfect health to a state as bad as 
dead), the corresponding values per statistical case are $3.6, $9.5, and $5.6 million. 
These values for a chronic illness as bad as dead are comparable to conventional 
estimates of the value per statistical life (e.g., Viscusi and Aldy 2003, Kochi et al. 
2006), which supports their plausibility.  
In summary, we find that it is possible to elicit internally consistent and 
apparently meaningful estimates of WTP to reduce risk of morbid health conditions 
using a generic health classification and utility system. Estimated WTP is 
significantly larger for conditions that are more severe (as measured by the loss in 
calculated HRQL) and of longer duration, but the variation of WTP with these 
dimensions is much less than proportionate. Estimated WTP is sensitive to 
supplementing the EQ-5D profile with the name of the disease. Estimated WTP is 
larger to reduce risk to another household member than to oneself, especially when 
the other is a child. Moreover, the relationships of WTP and HRQL to attributes of the 
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EQ-5D classification system are systematically different. These results suggest that 
accurate estimates of WTP to reduce risk of morbid conditions cannot be obtained by 
multiplying the expected reduction in QALY loss by a constant WTP per QALY 
value. More accurate estimates may be obtained using a concave function of the 
severity and duration of the illness like those estimated here, though our results 
suggest that economic valuation is a different function than HRQL of the EQ-5D 
attributes and also depends on aspects of the illness that are conveyed by 
supplementing the EQ-5D health profile with the name of the condition. 
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Table 1. Health Profiles, Illness Names, and Durations 
Health 
Profile 
EQ-5D  
Attribute Levels 
EQ-5D  
Score Name of Illness Possible Duration 
A M1 S1 U1 P2 A1 0.827 Influenza 1 month 
A M1 S1 U1 P2 A1 0.827 Respiratory Infection 1 month, 1 year 
A M1 S1 U1 P2 A1 0.827 Skin Cancer 1 month, 1 year 
B M1 S1 U1 P2 A2 0.800 Bronchitis 1 month, 1 year, Lifetime 
B M1 S1 U1 P2 A2 0.800 Lung Cancer Lifetime 
B M1 S1 U1 P2 A2 0.800 Migraine Headaches 1 month, 1 year, Lifetime 
B M1 S1 U1 P2 A2 0.800 Respiratory Infection 1 month, 1 year 
B M1 S1 U1 P2 A2 0.800 Skin Cancer 1 month, 1 year 
C M1 S1 U2 P2 A2 0.768 Hepatitis 1 month, 1 year, Lifetime 
C M1 S1 U2 P2 A2 0.768 Influenza 1 month 
D M2 S1 U2 P2 A2 0.708 Heart Disease Lifetime 
D M2 S1 U2 P2 A2 0.708 Hepatitis 1 month, 1 year, Lifetime 
D M2 S1 U2 P2 A2 0.708 Liver Cancer Lifetime 
D M2 S1 U2 P2 A2 0.708 Liver Disease Lifetime 
E M2 S2 U2 P2 A2 0.597 Parkinson's Disease Lifetime 
F M2 S1 U2 P3 A2 0.397 Bronchitis 1 month, 1 year, Lifetime 
F M2 S1 U2 P3 A2 0.397 Lung Cancer Lifetime 
G M1 S1 U2 P3 A3 0.289 Migraine Headaches 1 month, 1 year, Lifetime 
H M2 S2 U3 P3 A2 0.263 Liver Cancer Lifetime 
H M2 S2 U3 P3 A2 0.263 Liver Disease Lifetime 
J M3 S3 U3 P2 A1 0.145 Parkinson's Disease Lifetime 
K M3 S2 U2 P3 A2 0.086 Heart Disease Lifetime 
Note: EQ-5D attributes: M – Mobility, S – Self Care, U – Usual Activities, P – Pain/Discomfort,  
A – Anxiety/Depression. Level 1 is no problem, level 2 is a moderate problem, and level 3 is a severe problem. 
 
Table 2. Sample Means and Standard Deviations 
 Household Member at Risk 
Variable Pooled Self Child Other Adult
Baseline Risk is 4 in 10,000 per Year 0.505 0.510 0.514 0.495 
 (0.500) (0.500) (0.500) (0.500) 
Log of Risk Reduction -8.866 -8.867 -8.872 -8.863 
 (0.347) (0.347) (0.347) (0.347) 
Log of Loss in Health-Related Quality of Life -1.426 -1.490 -1.038 -1.512 
 (1288) (1.346) (0.807) (1.347) 
Log of Duration of Illness in Years 0.858 0.791 1.125 0.829 
 (2.642) (2.562) (2.957) (2.594) 
Named Illness 0.474 0.486 0.444 0.471 
 (0.499) (0.500) (0.497) (0.499) 
Current Health-Related Quality of Life 0.870 0.854 0.948 0.857 
 (0.160) (0.161) (0.121) (0.164) 
Current Health and Illness have same EQ-5D Profile 0.085 0.098 0.010 0.102 
 (0.279) (0.297) (0.098) (0.303) 
Risk is to Child in Household 0.159 0.000 1.000 0.000 
 (0.366) (0.000) (0.000) (0.000) 
Risk is to Other Adult in Household 0.364 0.000 0.000 1.000 
 (0.481) (0.000) (0.000) (0.000) 
Age of Other Person at Risk 41.66  9.786 47.23 
 (20.99)  (5.521) (17.09) 
Other Person at Risk is Male 0.497  0.524 0.494 
 (0.500)  (0.500) (0.500) 
Respondent’s Age 47.99 47.99 37.62 46.39 
 (17.03) (17.03) (11.15) (16.96) 
Male Respondent 0.489 0.489 0.477 0.505 
 (0.500) (0.500) (0.500) (0.500) 
Household Income (in thousand US$) 62.02 62.02 67.54 68.13 
 (43.54) (43.54) (42.52) (44.40) 
Log of Household Income 10.76 10.76 10.90 10.89 
 (0.838) (0.838) (0.740) (0.781) 
Respondent’s Education in Years 13.69 13.69 13.90 13.65 
 (2.633) (2.633) (2.431) (2.600) 
Black, Non-Hispanic Respondent 0.084 0.084 0.087 0.073 
 (0.278) (0.278) (0.282) (0.260) 
Hispanic Respondent 0.092 0.092 0.129 0.090 
 (0.289) (0.289) (0.336) (0.286) 
Other Race, Non-Hispanic Respondent 0.056 0.056 0.054 0.058 
 (0.231) (0.231) (0.225) (0.233) 
Sample Size 2,184 2,184 727 1,668 
Note: Standard deviations are in parentheses. 
 
Table 3. Basic WTP model     
 Household Member at Risk 
 Pooled Self Child Other Adult
Variable Model 1 Model 2 Model 3 Model 4 
Intercept 12.040*** 11.880*** 11.161*** 13.242***
 (1.220) (1.738) (3.301) (2.006) 
Baseline Risk is 4 in 10,000 per Year -0.057  0.065 -0.217 -0.148 
 (0.091) (0.130) (0.239) (0.150) 
Log of Risk Reduction  0.614***  0.635***  0.578*  0.600***
 (0.132) (0.189) (0.346) (0.218) 
Log of Loss in Health-Related Quality of Life  0.372***  0.358***  0.197  0.436***
 (0.057) (0.079) (0.179) (0.093) 
Log of Duration of Illness in Years  0.126***  0.118***  0.136***  0.137***
 (0.018) (0.027) (0.044) (0.031) 
Named Illness -0.516*** -0.483*** -0.921*** -0.396** 
 (0.094) (0.135) (0.251) (0.155) 
Current Health-Related Quality of Life -1.265*** -0.940**  0.542 -2.152***
 (0.331) (0.462) (1.045) (0.530) 
Health and Illness have same EQ-5D Profile  1.161***  0.863**  0.366  1.620***
 (0.251) (0.343) (1.327) (0.397) 
Risk is to Child in Household  1.060***    
 (0.136)    
Risk is to Other Adult in Household  0.541***    
 (0.100)    
Residual Standard Deviation  3.615  3.571  3.756  3.598 
 (0.064) (0.091) (0.171) (0.104) 
Sample Size  9,103  4,346  1,441  3,316 
Log Likelihood  -10,298 -4,900.9 -1,615.9 -3,771.8 
Note: Standard errors are in parentheses. ***, **, and * denote statistical significance at 1, 5, and 10 percent, respectively,  
based on likelihood-ratio tests. 
 
Table 4. Basic model with respondent and target characteristics 
 Household Member at Risk 
 Pooled Self Child Other Adult
Variable Model 1 Model 2 Model 3 Model 4 
Intercept  8.644***  8.214***  6.785* 10.560***
 (1.373) (1.947) (3.797) (2.249) 
Baseline Risk is 4 in 10,000 per Year -0.053  0.059 -0.214 -0.135 
 (0.091) (0.130) (0.239) (0.149) 
Log of Risk Reduction  0.608***  0.623***  0.569*  0.587***
 (0.131) (0.188) (0.345) (0.216) 
Log of Loss in Health-Related Quality of Life  0.376***  0.361***  0.179  0.445***
 (0.057) (0.079) (0.179) (0.093) 
Log of Duration of Illness in Years  0.129***  0.126***  0.134***  0.135***
 (0.018) (0.027) (0.043) (0.031) 
Named Illness -0.553*** -0.530*** -0.900*** -0.425***
 (0.095) (0.136) (0.251) (0.155) 
Current Health-Related Quality of Life -1.259*** -0.970**  0.627 -2.087***
 (0.343) (0.484) (1.049) (0.552) 
Current Health and Illness have same EQ-5D Profile  1.177***  0.899***  0.343  1.637***
 (0.251) (0.342) (1.325) (0.395) 
Risk is to Child in Household  1.201***    
 (0.200)    
Risk is to Other Adult in Household  0.600***    
 (0.102)    
Age of Other Person at Risk -0.000***  -0.017  0.001***
 (0.005)  (0.023) (0.006) 
Other Person at Risk is Male  0.040***   0.035*  0.283***
 (0.095)  (0.240) (0.184) 
Respondent Age  0.015***  0.012***  0.027**  0.018***
 (0.005) (0.004) (0.011) (0.006) 
Male Respondent -0.260*** -0.342***  0.093 -0.107 
 (0.095) (0.131) (0.243) (0.184) 
Log of Household Income  0.219***  0.276***  0.318*  0.080 
 (0.065) (0.090) (0.179) (0.108) 
Respondent’s Education in Years  0.042**  0.027  0.030  0.073** 
 (0.019) (0.027) (0.053) (0.032) 
Married Respondent -0.371*** -0.246* -0.909*** -0.427** 
 (0.102) (0.140) (0.278) (0.180) 
Residual Standard Deviation  3.597  3.559  3.729  3.563 
 (0.063) (0.090) (0.170) (0.103) 
Sample Size  9,080  4,346  1,434  3,300 
Log Likelihood  -10,245 -4,888.3 -1,601.8 -3,738.9 
Note: Standard errors are in parentheses. ***, **, and * denote statistical significance at 1, 5, and 10 percent, respectively,  
based on likelihood-ratio tests. 
 
Table 5. Basic model with illness names 
 Household Member at Risk 
 Pooled Self Child Other Adult
Variable Model 1 Model 2 Model 3 Model 4 
Intercept 11.759*** 11.530*** 10.919*** 13.245***
 (1.222) (1.741) (3.323) (2.004) 
Baseline Risk is 4 in 10,000 per Year -0.052  0.065 -0.228 -0.145 
 (0.091) (0.130) (0.239) (0.150) 
Log of Risk Reduction  0.618***  0.630***  0.584*  0.636***
 (0.132) (0.188) (0.346) (0.217) 
Log of Loss in Health-Related Quality of Life  0.299***  0.290***  0.083  0.371***
 (0.063) (0.087) (0.199) (0.103) 
Log of Duration of Illness in Years  0.069***  0.067***  0.111***  0.060***
 (0.022) (0.032) (0.052) (0.036) 
Influenza -1.108*** -0.995*** -0.895 -1.441***
 (0.260) (0.354) (0.664) (0.469) 
Respiratory Infection -0.518* -0.003 -1.382* -0.694 
 (0.286) (0.436) (0.751) (0.438) 
Bronchitis -0.592** -0.511 -0.450 -0.747* 
 (0.238) (0.345) (0.598) (0.391) 
Migraine Headaches -0.807*** -0.635** -0.869 -0.977***
 (0.201) (0.285) (0.556) (0.328) 
Parkinson's Disease -0.158  0.044 -0.433 -0.330 
 (0.200) (0.280) (0.594) (0.325) 
Heart Disease  0.022 -0.269 -0.611  0.674* 
 (0.216) (0.301) (0.597) (0.362) 
Hepatitis -0.718*** -0.817** -1.963*** -0.160 
 (0.249) (0.363) (0.709) (0.390) 
Liver Disease -0.336 -0.131 -1.125* -0.310 
 (0.255) (0.356) (0.636) (0.445) 
Liver Cancer -0.168 -0.355 -0.533  0.218 
 (0.244) (0.342) (0.670) (0.406) 
Skin Cancer -1.353*** -1.563*** -1.585** -0.972** 
 (0.278) (0.399) (0.711) (0.463) 
Lung Cancer  0.351  0.229 -0.538  0.864** 
 (0.254) (0.372) (0.643) (0.414) 
Current Health-Related Quality of Life -0.998*** -0.673  0.753 -1.870***
 (0.341) (0.479) (1.064) (0.544) 
Current Health and Illness have same EQ-5D Profile  1.088***  0.806**  0.095  1.562***
 (0.254) (0.346) (1.336) (0.403) 
Risk is to Child in Household  1.084***    
 (0.136)    
Risk is to Other Adult in Household  0.536***    
 (0.100)    
Residual Standard Deviation  3.606  3.558  3.743  3.575 
 (0.064) (0.090) (0.171) (0.104) 
Sample Size  9,103  4,346  1,441  3,316 
Log Likelihood  -10,281 -4,891.6 -1,613.1 -3,757.2 
Note: Standard errors are in parentheses. ***, **, and * denote statistical significance at 1, 5, and 10 percent, respectively,  
based on likelihood-ratio tests. 
Table 6. Basic model with baseline health and potential loss by EQ-5D attribute 
 Household Member at Risk 
 Pooled Self Child Other Adult
Variable Model 1 Model 2 Model 3 Model 4 
Intercept  8.985***  9.511*** 11.779***  9.029***
 (1.203) (1.721) (3.232) (1.984) 
Baseline Risk is 4 in 10,000 per Year -0.069  0.062 -0.248 -0.159 
 (0.091) (0.130) (0.240) (0.150) 
Log of Risk Reduction  0.603***  0.626***  0.546  0.597***
 (0.132) (0.188) (0.345) (0.217) 
Baseline Impairment in Mobility -0.104 -0.261 -1.848**  0.369 
 (0.168) (0.233) (0.813) (0.259) 
Baseline Impairment in Self-Care -0.623*** -0.804** -0.091 -1.209***
 (0.194) (0.339) (0.316) (0.402) 
Baseline Impairment in Usual Activities  0.323*  0.636***  0.277  0.184 
 (0.171) (0.245) (0.595) (0.269) 
Baseline Impairment in Pain and Discomfort  0.671***  0.520**  0.585  0.819***
 (0.152) (0.212) (0.638) (0.242) 
Baseline Impairment in Anxiety and Depression  0.127  0.058  0.020  0.236 
 (0.132) (0.186) (0.425) (0.212) 
Loss in Mobility  0.278**  0.375** -0.031  0.308* 
 (0.111) (0.161) (0.283) (0.185) 
Loss in Self-Care  0.085 -0.027  0.356  0.042 
 (0.139) (0.200) (0.370) (0.226) 
Loss in Usual Activities  0.077  0.059 -0.253  0.354* 
 (0.117) (0.167) (0.306) (0.196) 
Loss in Pain and Discomfort  0.245**  0.118  0.344  0.371* 
 (0.121) (0.173) (0.331) (0.196) 
Loss in Anxiety and Depression  0.163  0.288  0.180 -0.020 
 (0.124) (0.181) (0.319) (0.204) 
Log of Duration of Illness in Years  0.116***  0.113***  0.134***  0.117***
 (0.019) (0.028) (0.045) (0.031) 
Named Illness -0.515*** -0.504*** -0.918*** -0.373** 
 (0.095) (0.135) (0.253) (0.155) 
Current Health and Illness have same EQ-5D Profile  0.256  0.012 -0.305  0.703** 
 (0.202) (0.275) (1.316) (0.313) 
Risk is to Child in Household  1.292***    
 (0.141)    
Risk is to Other Adult in Household  0.535***    
 (0.100)    
Residual Standard Deviation  3.605  3.560  3.737  3.570 
 (0.064) (0.090) (0.170) (0.104) 
Sample Size  9,103  4,346  1,441  3,316 
Log Likelihood  -10,279 -4,890.2 -1,612.2 -3,755.5 
Note: Standard errors are in parentheses. ***, **, and * denote statistical significance at 1, 5, and 10 percent, respectively,  
based on likelihood-ratio tests. 
 
Table 7. Basic model with EQ-5D valuation variables 
 
HRQL 
Value 
Function 
Household Member at Risk 
 Pooled Self Child Other Adult
Model 1 Model 2 Model 3 Model 4 Variable 
Intercept  10.353*** 10.529*** 11.551*** 10.893*** 
  (1.174) (1.678) (3.136) (1.927) 
Baseline Risk is 4 in 10,000 per Year  -0.064  0.052 -0.228 -0.140 
  (0.091) (0.130) (0.240) (0.150) 
Log of Risk Reduction   0.609***  0.631***  0.592*  0.626*** 
  (0.132) (0.188) (0.345) (0.217) 
Loss to Level 2 Mobility 0.146  0.448*  0.996***  0.181 -0.064 
 (0.008) (0.231) (0.334) (0.691) (0.377) 
Loss to Level 3 Mobility 0.558  1.883***  2.620***  1.321  1.563 
 (0.016) (0.631) (0.954) (1.597) (1.042) 
Loss to Level 2 Self-Care 0.175  0.265  0.870*  0.339 -0.464 
 (0.008) (0.311) (0.469) (0.736) (0.526) 
Loss to Level 3 Self-Care 0.471  0.897  1.977**  0.077 -0.246 
 (0.016) (0.627) (0.911) (1.678) (1.042) 
Loss to Level 2 Usual Activities 0.140 -0.051 -0.067 -0.159  0.142 
 (0.008) (0.226) (0.331) (0.600) (0.374) 
Loss to Level 3 Usual Activities 0.374  1.221*  1.309  0.828  1.842* 
 (0.013) (0.629) (0.947) (1.670) (1.038) 
Loss to Level 2 Pain and Discomfort 0.173 -0.521*** -0.491*** -0.100 -0.572*** 
 (0.008) (0.119) (0.163) (0.589) (0.184) 
Loss to Level 3 Pain and Discomfort 0.537  0.329  0.263  0.623  0.518 
 (0.020) (0.294) (0.415) (0.998) (0.471) 
Loss to Level 2 Anxiety and Depression 0.156  0.132  0.331  0.011 -0.022 
 (0.008) (0.160) (0.228) (0.428) (0.273) 
Loss to Level 3 Anxiety and Depression 0.450  1.664***  3.157***  1.473  0.179 
 (0.015) (0.549) (0.852) (1.440) (0.891) 
Change in Number of Attributes at Level 2 Squared 0.011 -0.042  0.005 -0.074 -0.102 
 (0.002) (0.040) (0.058) (0.115) (0.066) 
Change in Number of Attributes at Level 3 -0.122  1.726***  2.967***  1.559  0.523 
 (0.018) (0.633) (0.977) (1.762) (1.005) 
Change in Number of Attributes at Level 3 Squared -0.015 -0.242 -0.436** -0.401  0.024 
 (0.003) (0.150) (0.220) (0.509) (0.226) 
Change in Number of Attributes at Level 2 or 3 -0.140  0.232  0.315  0.229  0.261 
 (0.010) (0.198) (0.291) (0.495) (0.334) 
Log of Duration of Illness in Years   0.117***  0.117***  0.125***  0.125*** 
  (0.019) (0.028) (0.045) (0.031) 
Named Illness  -0.500*** -0.461*** -0.885*** -0.370** 
  (0.095) (0.135) (0.253) (0.155) 
Current Health and Illness have same EQ-5D Profile   0.245 -0.084 -0.417  0.746** 
  (0.205) (0.281) (1.325) (0.321) 
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Table 7. Basic model with EQ-5D valuation variables 
 
HRQL 
Value 
Function 
Household Member at Risk 
 Pooled Self Child Other Adult
Variable Model 1 Model 2 Model 3 Model 4 
Risk is to Child in Household   1.280***    
  (0.141)    
Risk is to Other Adult in Household   0.540***    
  (0.100)    
Residual Standard Deviation   3.603  3.550  3.738  3.570 
  (0.064) (0.090) (0.171) (0.104) 
Sample Size   9,103  4,346  1,441  3,316 
Log Likelihood   -10,271 -4,877.2 -1,613.3 -3,757.7 
Note: Standard errors are in parentheses. ***, **, and * denote statistical significance at 1, 5, and 10 percent, respectively,  
based on likelihood-ratio tests. HRQL Value Function reported in Shaw et al. (2005); all of the reported coefficients are 
statistically significant at 1 percent. 
 
 
 
